ConductScience.org, home

Comparison · NCT03759639-deaths

Treatment With IB1001 vs Post-Treatment Washout: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Treatment With IB1001 vs Post-Treatment Washout: deaths from any cause. Trial comparisons, record NCT03759639-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03759639-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.104wilson
Risk in group 2000.11wilson
Risk difference, group 1 minus group 20-0.110.104newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Treatment With IB1001
Parent Study: 6-weeks treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~* Patients aged 6-12 years weighing 15 to \<25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~* Patients aged 6-12 years weighing 25 to \<35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~* Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)~IB1001: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
033EG000
Group 2Post-Treatment WashoutAfter the Parent Study 6-week treatment period, patients entered a 6-week post-treatment washout period.031EG001

Harm

What it counts
Total, all-cause mortality
Time frame
From signing of the informed consent form through to End of Study (Day 84, scheduled at 42 days post last IB1001 dose).

Source ClinicalTrials.gov

Trial

Title
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
NCT number
NCT03759639
Phases
PHASE2
Conditions
Niemann-Pick Disease, Type C
Interventions
IB1001
Lead sponsor
IntraBio Inc
Results first posted
2023-11-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03759639-deaths